Business Context and Reporting Period
Company: Isis Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2003
Business Overview: Isis is a biopharmaceutical company pioneering antisense technology for drug discovery and development. The company focuses on treating inflammatory, viral, metabolic, cardiovascular, and cancer diseases. Key programs include the development of Affinitak (non-small cell lung cancer), alicaforsen (Crohn's disease), and the Ibis program for infectious disease diagnostics.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2003 | Nine Months Ended Sep 30, 2002 |
|---|---|---|---|
| Total Revenue | $11,294 | $40,291 | $58,320 |
| Operating Expenses | $30,361 | $97,789 | $97,887 |
| Loss from Operations | $(19,067) | $(57,498) | $(39,567) |
| Net Loss | $(22,203) | $(69,621) | $(56,413) |
| Net Loss Applicable to Common Stock | $(22,378) | $(70,139) | $(57,305) |
| Diluted Net Loss Per Share | $(0.40) | $(1.27) | $(1.06) |
Liquidity and Balance Sheet Highlights (in thousands)
- Cash and Cash Equivalents: $55,792 (Sep 30, 2003) vs. $101,856 (Dec 31, 2002).
- Short-term Investments: $179,028 (Sep 30, 2003) vs. $187,497 (Dec 31, 2002).
- Total Current Assets: $255,242.
- Total Current Liabilities: $59,639.
- Working Capital: $195,603.
- Long-term Debt: Includes $125,000 in 5.5% convertible subordinated notes and significant partner debt (Lilly, Elan, Boehringer Ingelheim).
- Accumulated Deficit: $(530,032).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue for the nine months ended September 30, 2003, decreased by approximately 31% compared to the same period in 2002. This was primarily due to the conclusion of collaborations with Elan (Orasense and HepaSense) in late 2002 and reduced revenue from the clinical development of Affinitak.
- Operating Expenses: Total operating expenses remained relatively flat year-over-year for the nine-month period ($97.8M in 2003 vs. $97.9M in 2002). However, on a proforma basis (excluding stock option compensation and restructuring), expenses decreased by approximately 6% due to an expense reduction plan initiated in Q2 2003 and reduced Affinitak-related costs.
- Restructuring Charges: The company incurred a one-time restructuring charge of approximately $1.8 million in Q2 2003 following disappointing Phase III trial results for Affinitak. No such charge was recorded in the comparable 2002 period.
- Investment Losses: A non-cash loss of $2.4 million was recorded in Q1 2003 related to the impairment of equity investments in Antisense Therapeutics Limited (ATL) and Hybridon, Inc.
- Debt Reduction: Total debt obligations decreased slightly to $237.4 million from $242.6 million at year-end 2002, largely due to a renegotiation with Eli Lilly which waived repayment of a $21.2 million manufacturing loan.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Liquidity: Management believes that available cash, cash equivalents, short-term investments, investment income, and committed contractual payments from partners will be sufficient to meet anticipated requirements for at least the next 36 months.
- Affinitak: Following a Phase III trial in March 2003 that did not support a single-study New Drug Application (NDA), the company will not file an NDA in 2003. A decision on future development depends on the results of a second Phase III trial by partner Eli Lilly, expected in the second half of 2004.
- Alicaforsen: Two Phase III trials for Crohn's disease are ongoing, with enrollment expected to complete in the first half of 2004. Results are expected in the second half of 2004.
- New Funding: In September 2003, the Ibis program received a grant of up to $6.0 million from the CDC. In November 2003 (subsequent event), the company received a grant of up to $8.0 million from the Singapore Economic Development Board.
Risk Factors
- Clinical Trial Failure: High risk that drug candidates (including Affinitak) may fail to demonstrate safety or efficacy in clinical trials, preventing regulatory approval.
- Partner Dependence: Significant reliance on collaborative partners (e.g., Lilly, Elan) for funding and development. Partners may terminate agreements or fail to fund programs.
- Profitability: The company has incurred accumulated losses of approximately $530 million since inception and expects to incur additional operating losses in the future.
- Regulatory Approval: Failure to obtain FDA or other regulatory approvals would prevent commercialization of products.
Investor Verification Checklist
- Affinitak Trial Status: Verify the timeline and expectations for the second Phase III trial results from Eli Lilly, which are critical for the future of the company's most advanced asset.
- Liquidity Runway: Confirm the 36-month liquidity projection against current cash burn rates and potential delays in revenue recognition from partners.
- Revenue Recognition: Review the impact of EITF 00-21 on the timing of milestone revenue recognition for new and existing collaborations.
- Debt Covenants and Convertibility: Assess the terms of the $125 million convertible notes and partner debt, specifically regarding conversion prices and potential dilution.
- Inventory Valuation: Monitor the valuation of inventory, particularly given the write-down of Affinitak raw materials to zero in Q2 2003.